WINNIPEG, MANITOBA – July 17, 2008 – Sanomune Inc, a private biotechnology company developing novel treatments for neurological diseases, is pleased to announce that it will be presenting data on its lead compound, SAN-61, at the International Conference on Alzheimer’s Disease (ICAD) 2008. SAN-61, a safe and well-tolerated biological with an established history of human use, has been shown to drastically reduce amyloid beta toxicity in rat brain neuronal cultures. In the second half of 2008, Sanomune plans to file for regulatory clearance to start a 60 patient phase IIa clinical trial of SAN-61 aimed at testing a variety of cognitive measures and relevant biological markers associated with Alzheimer’s disease.

“We’re honoured to have been selected to present our results at the ICAD Hot Topics session,” said Rick Pauls, Sanomune’s President. “When combined with existing clinical data on SAN-61 and our recent data regarding MMP-9 activation, the evidence we have accumulated suggests SAN-61 could be an ideal Alzheimer’s therapy.” In addition to targeting soluble and fibril amyloid, in-vivo
research also appears to suggest that SAN-61 is involved in neuroregeneration and the regulation of tau protein through GSK-3beta inhibition. “This could be a therapy with multiple promising points of intervention.” Sanomune’s data can be viewed during ICAD’s Hot Topics Poster Session on Wednesday, July 30.

About ICAD – The Premier Alzheimer Conference
As a part of the Alzheimer’s Association research program, this international conference serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. This meeting will bring together more than 5,000 researchers, physicians and care providers from 60 countries – the largest group of international leaders in Alzheimer research and
care ever convened.

About Sanomune
Sanomune is a private biopharmaceutical start-up focused on neurological and autoimmune disorders. Sanomune’s lead product, SAN-61 is targeting the treatment of Alzheimer’s disease and other neurological conditions with a naturally-occurring, orally available protein.www.sanomune.com

About Cerebricon
Cerebricon Ltd. is a global collaborative and contract research organization, specializing in Preclinical models of CNS and PNS diseases for drug discovery and pharmacological research. Located in Kuopio, Finland with sales and marketing offices in London, UK and Los Angeles, USA. Cerebricon serves small, medium and large pharmaceutical companies as well as independent researchers and academic institutions around the globe. Cerebricon Ltd. is a completely privately owned company with fully proprietary staff and laboratories.www.cerebricon.com

For more information, please contact:

Rick Pauls
President
Sanomune Inc.
Phone: 204.477.7590
Fax: 204.453.1239